Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through
population PK in paediatric patients with opioid induced constipation (OIC) or at risk of
OIC.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca Kyowa Kirin Pharmaceutical Development Ltd